Loading viewer...
investor_presentation
Format: PDF investor_presentation
Aphios Pharma develops cannabis and hemp-based pharmaceutical drugs targeting cancer pain, opioid use disorder, and multiple sclerosis using novel drug delivery technologies. The company follows the FDA 505b(2) regulatory pathway to accelerate development and advance to Phase 2 clinical trials. Backed by Harvard Medical School expertise, Aphios combines natural cannabinoids with scientific rigor for nervous system disorder treatments.
investor_presentation
25 Pages
TBO.com
investor_presentation
TaskUs
investor_presentation
Calidus Resources